If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Bioprosthetic surgical aortic valve replacement remains an important treatment option in the era of transcatheter interventions. Real-world outcomes are not well characterized because of limited prospective follow-up studies. We present the 10-year clinical outcomes of Medicare beneficiaries undergoing surgical aortic valve replacement with a contemporary supra-annular porcine valve.
Methods
This is a single-arm observational study using Medicare fee-for-service claims data. De-identified patients undergoing surgical aortic valve replacement with the Epic Supra valve (Abbott) in the United States between January 1, 2008, and December 31, 2019, were selected by International Classification of Diseases 9th and 10th Revision procedure codes and then linked to a manufacturer device tracking database. All-cause mortality, heart failure rehospitalization, and aortic valve reintervention (surgical or transcatheter valve-in-valve) were evaluated at 10 years using the Kaplan–Meier method.
Results
Among 272,591 Medicare beneficiaries undergoing surgical aortic valve replacement during the study period, 11,685 received the Epic Supra valve, of whom 51.6% (6029) had underlying heart failure. Mean age was 76 ± 7 years. Survival at 10 years in patients without preoperative heart failure was 43.5% (95% confidence interval, 41.8-45.2) compared with 24.1% (95% confidence interval, 22.6-25.5) for patients with heart failure (P < .001). The 10-year freedom from heart failure rehospitalization was 64.0% (95% confidence interval, 62.6-65.3). Freedom from aortic valve reintervention was 94.6% (95% confidence interval, 93.8-95.3) at 10 years.
Conclusions
This real-world nationwide study of US Medicare beneficiaries receiving the Epic Supra valve demonstrates more than 94% freedom from all-cause valve reintervention and 64% freedom from heart failure rehospitalization at 10 years postimplant. Long-term survival and heart failure rehospitalization in this population with aortic valve disease undergoing surgical aortic valve replacement were found to be impacted by underlying heart failure.
SAVR remains an important treatment option for the Medicare population in the era of transcatheter valve interventions. Clinical outcomes are impacted most by preoperative HF and renal failure and the need for concomitant CABG or other cardiac valve surgery.
Over the past decade, there has been tremendous growth in the adoption of transcatheter aortic valve implantation (TAVI) as lower-risk patients became eligible for treatment and as continuous improvements were made in clinical outcomes and the available TAVI technology.
Although in recent years more patients within the Medicare population are undergoing TAVI, bioprosthetic surgical aortic valve replacement (SAVR) continues to remain an important treatment option for patients with aortic valve disease, especially those who require additional concomitant cardiac procedures.
A recent analysis of Medicare data showed that the acute clinical outcomes with TAVI have continued to improve over the last decade, whereas the clinical outcomes with SAVR have remained relatively unchanged considering SAVR is a more mature procedure.
Gaining insights into the long-term clinical outcomes of SAVR and the impact of underlying comorbidities and concomitant procedures would be informative to surgeons counseling patients who need an aortic valve replacement. The objective of this study is to assess the 10-year clinical outcomes of Medicare beneficiaries undergoing SAVR with the Epic Supra valve (Abbott, Santa Clara, Calif) in the era of transcatheter valve interventions.
Materials and Methods
Data Sources
This was a single-arm retrospective observational study using real-world data
derived from the Centers for Medicare & Medicaid Services (CMS) administrative claims data linked to a manufacturer device registration database (Abbott). Patient baseline characteristics (age, gender, race, and comorbidities), SAVR procedure date and hospital, and outcomes were identified from CMS fee-for-service (FFS) claims files. The manufacturer device registration database was used to determine the specific valve model and size implanted (Table E1). The use of CMS records linked with manufacturer device registration data was approved through a data use agreement with CMS (RSCH-2020-54878). The study protocol was approved on June 25, 2019, by Western Institutional Review Board (Institutional Review Board Study Number 1261727) with a waiver of informed patient consent because the study was a minimal risk database analysis.
Study Population
All Medicare beneficiaries undergoing SAVR with a bioprosthetic heart valve from January 1, 2008, to December 31, 2019, were identified using International Classification of Diseases, Ninth Revision (ICD-9) and Tenth Revision (ICD-10) codes (Table E2). Beneficiaries were excluded if they did not have continuous coverage in Medicare Part A and Part B for at least 12 months preceding the SAVR admission to allow for characterization of baseline comorbidities, using the Charlson and Elixhauser comorbidity algorithms
(Table E3). Manufacturer device registration data were linked to the CMS records using the probabilistic method with a combination of secondary patient identifiers (implant date, date of birth, gender, and implant hospital if available) as previously described.
For patients who underwent multiple SAVR procedures as identified in the CMS claims data, the index event was defined as the first hospitalization during which the Epic Supra valve (Abbott) was implanted. Beneficiaries with a diagnosis of endocarditis during the index hospitalization were identified using ICD-9 and ICD-10 diagnosis codes (Table E3) and were excluded from the analysis. The study cohort was followed from the date of implant until death, the end of Medicare FFS enrollment, the start of Medicare Advantage program enrollment, or the end of data availability (December 31, 2020), whichever came first.
The presence of concomitant procedures including coronary artery bypass grafting (CABG) or other cardiac valve surgery (surgical mitral/tricuspid/pulmonary valve repair or replacement) during the SAVR hospitalization was identified using ICD-9 and ICD-10 procedure codes (Table E3). A subgroup analysis on patients with isolated SAVR that excludes patients who underwent a concomitant CABG or other cardiac valve surgery was performed. The isolated SAVR subgroup also excluded patients with a redo SAVR, which was defined as having a prior TAVI or a prior surgical aortic valve repair or replacement. The use of acute mechanical circulatory support or a diagnosis of cardiogenic shock during the index hospitalization was used as a proxy for emergency SAVR and was also excluded from the isolated SAVR subgroup (Table E3).
The Epic Supra valve (Abbott) is a bioprosthetic heart valve that incorporates a triple composite design and is manufactured from selected porcine valve cusps that are matched for optimum leaflet coaptation and hemodynamics.
The Epic Supra valve was approved for commercial use in the United States in November 2007.
Clinical Outcomes
The study objective was to evaluate long-term clinical outcomes in a real-world setting including survival, freedom from heart failure (HF) rehospitalization, and freedom from reintervention at 10 years post-SAVR. Date of death was acquired from the CMS Master Beneficiary Summary File and was used to calculate the survival time and all-cause mortality. Operative mortality was defined as any mortality encountered through 30 days postimplant or during the index hospitalization, whichever occurred later. A HF rehospitalization was identified as any inpatient encounter after SAVR with a primary diagnosis of HF (Table E3), as previously described.
Aortic valve reintervention was defined as including a subsequent surgical valve replacement with a bioprosthetic or mechanical heart valve or a transcatheter valve-in-valve (VIV) implantation within the Epic Supra valve (Table E4). A terminal end point was evaluated at 10 years postimplant, which included left ventricular assist device (LVAD) implant or heart transplant. The valve reintervention end point and terminal end point were identified using the corresponding ICD-9 and ICD-10 procedure codes (Table E4) in the CMS inpatient claims after the index SAVR hospitalization.
Statistical Analysis
Patients' baseline demographics and operative details were summarized using standard statistics, such as mean (standard deviation) and count (percentage) as appropriate. Operative mortality and the terminal end point were reported in crude rates as the number of events divided by the total number of patients in the applicable cohort. Cumulative incidence rates per person-year were presented for all-cause rehospitalization and HF rehospitalization. Survival curves and estimates for 10-year survival, freedom from HF rehospitalization, and freedom from reintervention were generated using the Kaplan–Meier method. Differences between curves were compared using the log-rank test. Cox proportional hazards models were applied to all-cause mortality and HF rehospitalization outcomes in subgroup analyses. Independent predictors of 10-year mortality and HF rehospitalization were determined using multivariable Cox regression models. All P values were based on 2-sided tests. All analyses were performed using SAS 9.4 (SAS Institute, Inc).
Results
Study Cohort
Of 244,420 Medicare FFS beneficiaries who underwent a SAVR during the study period and had at least 1 year of continuous enrollment in Medicare FFS before the index SAVR, 11,964 received the Epic Supra valve according to the manufacturer device registration database. After excluding 279 beneficiaries who had a diagnosis of endocarditis at the index admission, all outcomes were derived from the remaining 11,685 patients (Figures 1 and E1). The Epic Supra valve implants were performed at more than 650 medical centers across all states of the United States.
Figure 1Real-world clinical outcomes of SAVR with the Epic Supra Valve (Abbott) in a Medicare Population. SAVR, Surgical aortic valve replacement; PDT, patient device tracking; CMS, Center for Medicare & Medicaid Services; FFS, fee-for-service; HF, heart failure.
Baseline patient demographics and medical history are presented in Table 1. The mean age of the study cohort was 76.3 ± 7.1 years with an average follow-up of 5.2 ± 3.3 years post-SAVR. Women represented 39.5% (n = 4615) of the study cohort, and 93.7% (n = 10,946) were White. The baseline age, gender, and race for the study cohort were similar to the baseline demographics of patients with bioprosthetic SAVR who were not linked to the manufacturer device registration database. The Medicare study cohort was characterized by a high burden of comorbidities, including 51.6% (n = 6029) with HF, 33.6% (n = 3924) with atrial fibrillation, and 25.8% (n = 3016) with renal failure, including 2.0% (n = 229) on dialysis.
Table 2 shows the SAVR operative details. More than 60% of the patients underwent SAVR between 2008 and 2011, before the commercial introduction of TAVI in the United States and other options for bioprosthetic SAVR. During the index hospitalization, 44.9% (n = 5243) of the study cohort underwent a concomitant CABG procedure and 11.2% (n = 1307) had other concomitant cardiac valve surgery. The proportion of isolated SAVR versus the overall number of SAVR cases remained relatively stable over the study period (Table E5). The 2 most commonly used valve sizes for the Epic Supra valve were 23 mm (34.0%, n = 3969) and 21 mm (29.9%, n = 3497). The overall hospital length of stay for the index hospitalization of SAVR was 10.6 ± 8.8 days.
Table 2Operative details
Variable
N = 11,685
Implanted valve size, mm
19
1349 (11.5%)
21
3497 (29.9%)
23
3969 (34.0%)
25
2218 (19.0%)
27
652 (5.6%)
Concomitant procedures
CABG
5243 (44.9%)
Other cardiac valve repair or replacement (mitral, tricuspid, or pulmonary)
1307 (11.2%)
Prior SAVR, surgical aortic valve repair, or prior TAVI
44 (0.4%)
Emergency SAVR
903 (7.7%)
Nonemergency and non-redo procedures
10,744 (91.9%)
Isolated SAVR
5356 (45.8%)
SAVR + CABG
4290 (36.7%)
SAVR + valve repair or replacement (mitral/tricuspid/pulmonary)
703 (6.0%)
SAVR + CABG + valve repair or replacement (mitral/tricuspid/pulmonary)
Operative mortality for the overall Medicare cohort was 5.7%. Within various subgroups, patients undergoing isolated SAVR had the lowest mortality (3.1%) followed by those with concomitant procedures: 4.0% in patients with concomitant CABG, 8.8% in patients with other cardiac valve surgery, and 9.9% in patients with concomitant CABG and other cardiac valve surgery (Figure E2). Operative mortality was the highest for patients undergoing emergency SAVR at 24.6%.
Long-Term Outcomes
During the 10 years after SAVR, fewer than 11 patients (<0.1%) met the terminal end point of LVAD implant or heart transplant. The all-cause rehospitalization rate was 0.69 per person-year and HF rehospitalization was 0.08 per person-year.
Long-term clinical outcomes are presented in Figure 2. The 10-year Kaplan–Meier estimates of survival and freedom from HF rehospitalization were 33.5% (95% confidence interval [CI], 32.4-34.6) and 64.0% (95% CI, 62.6-65.3), respectively (Figure 2, A and B). At 10 years postimplant, there were 185 repeat SAVR procedures and 95 transcatheter VIV procedures, and the freedom from all-cause reintervention was 94.6% (95% CI, 93.8-95.3) (Figure 2, C). When considering the competing risk of death, the 10-year cumulative incidence rate of reintervention was 3.2% (95% CI, 2.8-3.6). Among the 185 repeat SAVR procedures, there were 59 cases with a diagnosis of endocarditis at the time of reoperation, whereas none of the 95 VIV procedures were associated with a diagnosis of endocarditis.
Figure 2A, Kaplan–Meier 10-year survival. B, Kaplan–Meier 10-year freedom from HF rehospitalization. C, Kaplan–Meier 10-year freedom from all-cause aortic valve reintervention (reintervention includes repeat SAVR or a transcatheter VIV intervention, where patients were also censored at left ventricular assist device implant or heart transplantation). CI, Confidence interval; HF, heart failure.
SAVR patients without a preoperative diagnosis of HF were associated with better survival at 10 years compared with those with a preoperative diagnosis of HF (43.5% vs 24.1%, log-rank P < .0001) (Figure 3). The magnitude of this trend in the 10-year survival in patients without versus with preoperative HF increased slightly in the subgroup of isolated SAVR (48.3% vs 26.3%, log-rank P < .0001; Figure E3). Consistent with the trend in operative mortality, the 10-year Kaplan–Meier survival among isolated SAVR patients was 37.4% (95% CI, 35.7-39.1), and was sequentially lower at 34.5% (95% CI, 32.6-36.4) for those with concomitant CABG; 29.2% (95% CI, 24.9-33.6) for those with concomitant other cardiac valve surgery; and 20.9% (95% CI, 16.0-26.2) for those with both concomitant CABG and other cardiac valve surgery (log-rank P < .0001) (Figure 4).
Figure 4Kaplan–Meier 10-year survival stratified by SAVR subgroups with concomitant procedures. Isolated SAVR shown in blue. SAVR with concomitant CABG shown in red. SAVR with concomitant other cardiac valve repair or replacement (mitral, tricuspid, or pulmonary) shown in green. SAVR with concomitant CABG and other cardiac valve repair or replacement shown in yellow. CI, Confidence interval; SAVR, surgical aortic valve replacement; CABG, coronary artery bypass grafting; VALVE, other cardiac valve repair or replacement (mitral, tricuspid, or pulmonary); HR, hazard ratio.
Similar trends were observed for the 10-year freedom from HF rehospitalization (Figures E4 and E5). In the subgroup of isolated SAVR, the freedom from HF rehospitalization at 5 years and 10 years postimplant was 83.2% (95% CI, 82.1-84.3) and 69.1% (95% CI, 67.2-70.9), respectively (Figure E5).
The 10-year survivals and hazard ratios (HRs) for all-cause mortality are summarized for various subgroups of interest in Figure 5. Differences in 10-year mortality were observed across subgroups based on age, concomitant surgery, and medical history. Similar results were observed for 10-year HF rehospitalization (Figure E6).
Figure 5Subgroup analyses for 10-year survival.1 Kaplan–Meier for survival.2 HR for mortality.3 Redo = history of prior TAVI or surgical aortic valve repair/replacement. Vertical line represents the overall 10-year survival (33.5%). KM, Kaplan–Meier; CI, confidence interval; CABG, coronary artery bypass grafting; SAVR, surgical aortic valve replacement; HFH, heart failure rehospitalization.
The 10-year survival ranged from 38.4% in patients without renal failure to 19.5% in patients with renal failure without dialysis and 7.5% in patients with renal failure on dialysis. The 1-year survival for isolated SAVR in patients on dialysis was 70.3% (95% CI, 59.7-78.5). Freedom from rehospitalization for HF at 10 years postimplant ranged from 68.4% in patients without renal failure to 26.8% for patients with renal failure requiring dialysis (Figure E6).
Independent Predictors
Table 3 shows the independent predictors for 10-year all-cause mortality. After adjusting for other covariates, patient age and the presence of concomitant procedures were significantly associated with the 10-year mortality after SAVR. The top 2 independent predictors of the 10-year mortality were baseline renal failure (HR, 1.46; 95% CI, 1.38-1.55) and HF (HR, 1.41; 95% CI, 1.33-1.49). These 2 independent predictors along with performing a concomitant other cardiac valve surgery were among the top 3 predictors of the 10-year HF rehospitalization (renal failure HR, 1.60; 95% CI, 1.46-1.74; HF HR, 1.48; 95% CI, 1.35-1.61; and other cardiac valve surgery HR, 1.54; 95% CI, 1.37-1.73) (Table E6). Patients who underwent a concomitant other cardiac valve surgery had a higher incidence of HF and renal failure preoperatively compared with the rest of the patients, which increases the risk for reduced survival and more HF rehospitalizations (Table E5).
This real-world nationwide study of US Medicare beneficiaries undergoing SAVR with the Epic Supra valve between 2008 and 2019 demonstrates that long-term clinical outcomes are impacted by underlying comorbidities and the need for concomitant cardiac procedures. Unlike prior studies limited to isolated SAVR in the Medicare population,
this study provides clinical outcomes over 10 years of follow-up using a single bioprosthetic valve choice for a broader SAVR population undergoing various combinations of concomitant cardiac procedures. The observed operative mortality through 30 days or during the index hospitalization ranged from 3.1% for isolated SAVR to 24.6% for emergency SAVR with an overall average of 5.7% for the entire population. These outcomes are consistent with data from a recent study by Lauck and colleagues
examining temporal changes in mortality after SAVR and TAVI in a Medicare population, where the 30-day mortality remained relatively unchanged at 4.5% ± 0.2% for SAVR and decreased from 6.3% to 2.0% for TAVI between 2012 and 2019, respectively.
reported a decrease in hospital length of stay from 12.2 to 10.5 days for SAVR versus from 9.1 to 3.5 days for TAVI, where the reported length of stay for SAVR is consistent with our data.
using a Medicare population who underwent isolated SAVR between 2000 and 2009, it was demonstrated that the presence of preoperative HF was associated with an increased operative mortality of 8.5% versus 3.5%. Additionally, it was shown that operative mortality increased from 7.4% to 19.2% depending on the number of preoperative HF hospitalizations. In the same study, it was shown that long-term survival for patients undergoing isolated SAVR was influenced by the presence of preoperative HF, where the survival for patients without preoperative HF at 10 years postimplant versus with preoperative HF aligns with the results of our study (48.3% vs 26.3%, respectively). Our subgroup analyses similarly showed a trend of decreasing 10-year survival as the number of HF rehospitalizations in the year before SAVR increased.
the cumulative incidence of rehospitalization for HF in a Medicare population who underwent isolated SAVR between 2000 and 2004 was 17% at 5 years postimplant. It was also shown that the cumulative incidence of HF rehospitalization increased as the number of HF hospitalizations in the year before SAVR increased. Both of these observations are consistent with our findings.
Preoperative renal failure was also found to be a strong influencer for long-term survival and rehospitalization for HF. Mentias and colleagues
compared clinical outcomes between SAVR and TAVI performed between 2015 and 2017 in Medicare beneficiaries with end-stage renal disease on hemodialysis. The reported 30-day mortality for patients undergoing SAVR was higher than for those undergoing TAVI (12.8% vs 4.6%, P < .001). However, this difference subsequently decreased at 1 year postimplant (31.0% vs 28.1%, P = .1). In a similar study by Kobrin and colleagues
with procedures performed in 2011 and 2012, there was also no difference in the 1-year survival between SAVR and TAVI (63.6% vs 60.0%, log-rank P = .99). A similar survival at 1 year postimplant for patients on dialysis undergoing isolated SAVR was observed in our study.
Patients requiring concomitant procedures such as CABG and other cardiac valve replacement or repair surgery (mitral, tricuspid, or pulmonary) had an increase in operative mortality with a reduced long-term survival and more rehospitalization for HF compared with patients undergoing an isolated SAVR. The addition of CABG resulted in a modest increase in operative mortality, whereas the addition of other cardiac valve surgery had a more substantial increase in operative mortality. Patients requiring additional cardiac valve surgery had a higher incidence of preoperative HF (73.7% vs 49.7%), which may explain the higher observed operative mortality, reduced long-term survival, and long-term increase in HF rehospitalization.
It is anticipated that with TAVI being performed in lower-risk Medicare patients, there will be a corresponding relative decrease in the number of isolated SAVRs being performed over time.
However, because Food and Drug Administration approval for low-risk patients undergoing TAVI did not occur until August 2019, this trend was not observed in our study cohort with implants performed between 2008 and 2019. Surgeons engaged in counseling patients with aortic valve disease who may not be suitable candidates for TAVI and needing to undergo a concomitant cardiac surgery may use the data from our study to inform patients of the anticipated survival and the risk for HF rehospitalization after SAVR. Long-term outcomes are primarily driven by the presence of preoperative HF and renal failure and the need for concomitant procedures, providing potential guidance on clinical decision-making regarding treatment options such as SAVR versus TAVI.
The design of the Epic Supra valve is based on the Biocor valve except for having the Linx anticalcification treatment.
The Biocor valve was first introduced in 1982 and has more than 25 years of proven durability with a freedom from all-cause valve reoperation of 90.6% at 10 years postimplant.
In this real-world nationwide study, the freedom from all-cause valve reintervention at 10 years postimplant was 94.6%, which is consistent with the 97.3% ± 0.5% freedom from reintervention due to structural valve deterioration reported at 10 years after implant from Leipzig University for all patients undergoing SAVR with the Epic valve.
Approximately one-third of the patients undergoing valve reintervention in our study were managed successfully with a transcatheter VIV intervention.
Study Limitations
The study results are based on site-reported administrative Medicare claims data, in which the derived patient characteristics and procedural data are dependent on the billing codes used to support reimbursement for healthcare services rather than research purposes. Because of inherent limitations within the billing codes, certain parameters, such as the underlying aortic valve disease etiology, left ventricular ejection fraction, and New York Heart Association HF classification status, are unknown. Additionally, at the time of valve reintervention the exact mode of structural valve deterioration is unknown. However, the Medicare claims data have been found to be extremely informative and validated as a useful data source for gaining insights into the clinical outcomes associated with a wide range of procedures including surgical and transcatheter cardiac valve interventions.
Use of administrative claims to assess outcomes and treatment effect in randomized clinical trials for transcatheter aortic valve replacement: findings from the EXTEND study.
Although the Medicare data do not provide New York Heart Association HF functional status, the number of HF hospitalizations in the year before implant may be used as an indicator for HF severity.
Approximately 98% of the United States population aged 65 years or older are covered by Medicare insurance plans.
Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US.
However, this study is limited to Medicare FFS beneficiaries and does not include patients enrolled in the Medicare Advantage plans due to limitations in data availability. Between 2008 and 2019, FFS Medicare represented 64% to 78% of all Medicare beneficiaries.
Medicare Advantage patients are generally similar to Medicare FFS in terms of demographics, with a recent trend of having younger and more non-White patients.
Although not all Medicare beneficiaries or Epic Supra valve implants were captured in this study, the data from this study represent the population that is most commonly treated with SAVR and are informative to patients contemplating SAVR because the results obtained may be used to predict clinical outcomes depending on individual patient comorbidities, such as HF and renal failure, and the need for any concomitant procedures.
Finally, the findings from this study observed in the Medicare population may not be generalized to younger populations, who may have improved survival with reduced HF hospitalization but with a higher incidence of aortic valve reintervention.
undergoing isolated SAVR shows similar age (76 years), gender (45%-50% female), and race (93% White), such that the results from this study may be generalized to other Medicare patients. It is uncertain whether the results of this study may be generalized to non-White minority patients because 93% of the patients in this study were White. Further, the results from this study are specific to the Epic Supra valve and may not be generalized to SAVR with bioprosthetic valves from other medical device manufacturers.
Conclusions
This nationwide study reflects the real-world experience of Medicare beneficiaries undergoing SAVR with the Epic Supra valve and demonstrates that clinical outcomes are influenced by underlying comorbidities and the need for concomitant procedures. Renal failure and HF were found to be the 2 top predictors impacting long-term survival and HF rehospitalization. Overall, the Epic Supra valve had excellent durability with more than 94% freedom from all-cause reinterventions at 10 years postimplant and is a suitable choice for SAVR in the Medicare population.
Conflict of Interest Statement
R.J.W. and L.Y.L. are consultants to Abbott. Y.Y., J.B.P., and D.G. are employees of Abbott. All other authors reported no conflicts of interest.
The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.
Appendix E1
Figure E1Study cohort diagram. FFS, Fee-for-service; CMS, Center for Medicare & Medicaid Services; SAVR, surgical aortic valve replacement; CABG, coronary artery bypass grafting; VALVE, other cardiac valve repair or replacement (mitral, tricuspid, or pulmonary).
Figure E5Kaplan–Meier 10-year freedom from HF rehospitalization stratified by SAVR subgroups with concomitant procedures. Isolated SAVR shown in blue. SAVR with concomitant CABG shown in red. SAVR with concomitant other cardiac valve repair or replacement (mitral, tricuspid, or pulmonary) shown in green. SAVR with concomitant CABG and other cardiac valve repair or replacement shown in yellow. HF, Heart failure; CI, confidence interval; SAVR, surgical aortic valve replacement; CABG, coronary artery bypass grafting; HR, hazard ratio; VALVE, other cardiac valve repair or replacement (mitral, tricuspid, or pulmonary).
Figure E6Subgroup analyses for 10-year freedom from HF rehospitalization. 1 Kaplan–Meier for freedom of HF rehospitalization.2 HR for HF rehospitalization.3 Redo = history of prior TAVI or surgical aortic valve repair/replacement.4 Not available due to no data available at 10 years. Vertical line represents the overall 10-year freedom from HF rehospitalization (64.0%). KM, Kaplan–Meier; HF, heart failure; CI, confidence interval; CABG, coronary artery bypass grafting; SAVR, surgical aortic valve replacement; HFH, heart failure rehospitalization.
Due to the nonspecificity of ICD-9-PCS codes for the type of heart valves, additional codes are included in the linkage process to identify all the potential tissue heart valves in CMS claims.
Due to the nonspecificity of ICD-9-PCS codes for the type of heart valves, additional codes are included in the linkage process to identify all the potential tissue heart valves in CMS claims.
Due to the nonspecificity of ICD-9-PCS codes for the type of heart valves, additional codes are included in the linkage process to identify all the potential tissue heart valves in CMS claims.
ICD-9, International Classification of Diseases, Ninth Revision; PCS, procedure coding system; ICD-10, International Classification of Diseases, Tenth Revision.
∗ Due to the nonspecificity of ICD-9-PCS codes for the type of heart valves, additional codes are included in the linkage process to identify all the potential tissue heart valves in CMS claims.
All comorbidities were assessed for all available inpatient and outpatient claims before the index SAVR hospitalization (excluding the SAVR admission). From Elixhauser and Charlson comorbidity code algorithms. Coding based on Moore BJ, White S, Washington R, Coenen N, Elixhauser A. Identifying increased risk of readmission and in-hospital mortality using hospital administrative data: The AHRQ Elixhauser Comorbidity index. Med Care. 2017;55:698-705 and HCSRN: Health care systems research network http://hcsrn.org/sas/standard_macros.sas; Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-9. ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; PCS, procedure coding system; ICD-10-CM, International Classification of Diseases, 10th Revision, Clinical Modification; CABG, coronary artery bypass grafting; MCS, mechanical circulatory support.
Use of administrative claims to assess outcomes and treatment effect in randomized clinical trials for transcatheter aortic valve replacement: findings from the EXTEND study.
Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US.
Approved on June 25, 2019, by Western Institutional Review Board (Institutional Review Board Study No. 1261727) with a waiver of informed consent and a Health Insurance and Portability and Accountability Act waiver for using a deidentified database.
This study was sponsored by Abbott Structural Heart, which was responsible for acquiring and analyzing the data and for collaborating with the investigators regarding the preparation and submission of this manuscript. The authors had freedom to explore the data with final authority to submit the manuscript for publication. The manuscript was drafted and edited by the authors, who had full access to the results.
Read at the 102nd Annual Meeting of The American Association for Thoracic Surgery, Boston, Massachusetts, May 14-17, 2022.
00312-6&id=fx1.jpg){kind=link}
00312-6&id=fx2.jpg){kind=link}
00312-6&id=gr1.jpg){kind=link}
00312-6&id=gr2.jpg){kind=link}
00312-6&id=gr3.jpg){kind=link}
00312-6&id=gr4.jpg){kind=link}
00312-6&id=gr5.jpg){kind=link}
00312-6&id=fx3.jpg){kind=link}
00312-6&id=fx4.jpg){kind=link}
00312-6&id=fx5.jpg){kind=link}
00312-6&id=fx6.jpg){kind=link}
00312-6&id=fx7.jpg){kind=link}
00312-6&id=fx8.jpg){kind=link}